{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:22:41Z","timestamp":1760955761136},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ejca.2017.10.026","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T23:45:26Z","timestamp":1511826326000},"page":"67-76","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma"],"prefix":"10.1016","volume":"88","author":[{"given":"Katrin","family":"Schaper-Gerhardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Okoye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen S.","family":"Utikal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Dippel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imke","family":"Satzger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Sucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.10.026_bib1","first-page":"581","article-title":"Developments in targeted therapy in melanoma","author":"Amann","year":"2016","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.ejca.2017.10.026_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","article-title":"Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials","volume":"1","author":"Larkin","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2017.10.026_bib3","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.026_bib4","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/annonc\/mdv255","article-title":"The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600","volume":"26","author":"Massi","year":"2015","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.ejca.2017.10.026_bib5","first-page":"1","article-title":"Malignant melanoma S3-guideline \u201cdiagnosis, therapy and follow-up of melanoma\u201d","volume":"11","author":"Pflugfelder","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejca.2017.10.026_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.10.026_bib7","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.10.026_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.10.026_bib9","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.026_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials","volume":"28","author":"Madore","year":"2015","journal-title":"Pigment cell & melanoma Res"},{"key":"10.1016\/j.ejca.2017.10.026_bib11","first-page":"113","article-title":"Efficacy of nivolumab (NIVO) plus ipilimumab (IPI) combination in patients with advanced melanoma (MEL) and elevated serum lactate dehydrogenase (LDH): a pooled analysis","volume":"30","author":"Larkin","year":"2017","journal-title":"Pigment cell & melanoma Res"},{"key":"10.1016\/j.ejca.2017.10.026_bib12","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ejca.2017.10.026_bib13","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2017.10.026_bib14","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2017.10.026_bib15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.10.026_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.10.026_bib17","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","article-title":"Initial efficacy of anti-Lymphocyte Activation Gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab in patients with melanoma previously treated with anti\u2013PD-1\/PD-L1 therapy","volume":"35","author":"Acierto","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.026_bib18","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1111\/jdv.14106","article-title":"PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy","author":"Steiniche","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2017.10.026_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2326-6066.CIR-13-0034","article-title":"PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival","volume":"1","author":"Lipson","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2017.10.026_bib20","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","article-title":"In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas","volume":"20","author":"Schalper","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.026_bib21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.10.026_bib22","doi-asserted-by":"crossref","first-page":"9527","DOI":"10.1200\/JCO.2017.35.15_suppl.9527","article-title":"PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E\/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.026_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2017.03.012","article-title":"Baseline beta-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients","volume":"78","author":"Massi","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.10.026_bib24","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","article-title":"Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma","author":"Vilain","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.10.026_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40291-016-0237-9","article-title":"An analytical comparison of Dako 28-8 PharmDx assay and an E1L3N Laboratory-developed test in the immunohistochemical detection of programmed death-ligand 1","volume":"21","author":"Cogswell","year":"2017","journal-title":"Mol Diagn Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T19:22:23Z","timestamp":1570389743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917313667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":25,"alternative-id":["S0959804917313667"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.10.026","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}